Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes, according to a ...

A scientist at Cincinnati Children's who has hunted for decades for ways to shrink the painful and disfiguring nerve tumors ...

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class small molecule drugs that inhibit hypoxia-inducible factors 1 ...

A research team led by Professor Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU) has made a significant breakthrough in understanding how cancer cells develop ...

In 2001, imatinib was the first proof that small molecule inhibitors targeting molecular drivers of cancer could be an ...

Serotonin reuptake inhibitors (SRIs) are a class of drugs that affect the brain’s serotonin system, and doctors most commonly prescribe them as antidepressants. SRIs increase the levels of serotonin ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...